ANAB
ANAPTYSBIO, INC
Key Financials
Operating Income
$47.9M
↑ 141.7%
Net Income
$-13232000
↑ 90.9%
Revenue
$234.6M
↑ 157.0%
EPS (Diluted)
$-0.46
↑ 91.0%
Shareholders' Equity
$37.2M
↓ 47.5%
Total Assets
$364.4M
↓ 24.7%
Operating Cash Flow
$19.7M
↑ 114.6%
Cash & Equivalents
$238.2M
↑ 93.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 10/2/2026 | View on SEC |
| 144 | 10/1/2026 | View on SEC |
| 10-KT | 9/21/2026 | View on SEC |
| 8-K | 9/21/2026 | View on SEC |
| 4 | 9/17/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 8-K | 8/11/2026 | View on SEC |
| 4 | 8/7/2026 | View on SEC |
| 4 | 8/7/2026 | View on SEC |
| 8-K | 7/30/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ANAB |
| Company Name | ANAPTYSBIO, INC |
| CIK | 1370053 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0630 |
| State of Incorporation | DE |
| Phone | 858-362-6295 |